Li Chunyuan, Zhang Wei, Zhao Danqing, Yang Pei, Wan Wei, Liu Shuozi, Jing Hongmei
Department of Hematology, Lymphoma Center, Peking University, Third Hospital, Beijing, China.
Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
Leuk Res. 2022 Dec;123:106980. doi: 10.1016/j.leukres.2022.106980. Epub 2022 Oct 21.
This study aimed to retrospectively evaluate a large Chinese cohort's baseline characters and develop a new predictive scoring system.
A total of 491 FL patients were reviewed, and 337newly diagnosed 1-3a FL patients from January 2010 to October 2020 were enrolled in our retrospective cohort.
Progression-free survival (PFS) was assessed as the first endpoint; the 2-year and 5-year PFS were 81.4% and 67.8%, respectively. A new risk scoring system (SLMR) was established after the univariable and multivariable analyses, and four independent factors such as β2-MG, LDH, LMR, the number of nodal areas ≥ 5, and spleen involvement were detected by FDG-PET imaging were included. The SLMR was compared with the existing models using discrimination and calibration, and k-fold cross-validation was performed for internal validation. Our cohort classified patients into three groups (low-, intermediate- and high) according to the SLMR and showed the best model performance, especially for FL3a and received rituximab maintenance after induction therapy patients.
本研究旨在回顾性评估一个大型中国队列的基线特征，并开发一种新的预测评分系统。
共回顾了491例滤泡性淋巴瘤（FL）患者，2010年1月至2020年10月新诊断的337例1-3a期FL患者纳入我们的回顾性队列。
将无进展生存期（PFS）作为首要终点进行评估；2年和5年PFS分别为81.4%和67.8%。经过单变量和多变量分析后建立了一种新的风险评分系统（SLMR），纳入了β2-微球蛋白、乳酸脱氢酶、淋巴细胞与单核细胞比值、≥5个淋巴结区域的数量以及通过氟代脱氧葡萄糖正电子发射断层显像（FDG-PET）检测到的脾脏受累等4个独立因素。使用区分度和校准将SLMR与现有模型进行比较，并进行k折交叉验证以进行内部验证。我们的队列根据SLMR将患者分为三组（低、中、高），显示出最佳的模型性能，特别是对于FL3a期且诱导治疗后接受利妥昔单抗维持治疗的患者。
